<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:12:25Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10360425" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10360425</identifier>
        <datestamp>2023-07-22</datestamp>
        <setSpec>bmjo</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMJ Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id>
              <journal-id journal-id-type="hwp">bmjopen</journal-id>
              <journal-id journal-id-type="publisher-id">bmjopen</journal-id>
              <journal-title-group>
                <journal-title>BMJ Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2044-6055</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10360425</article-id>
              <article-id pub-id-type="pmcid">PMC10360425</article-id>
              <article-id pub-id-type="pmc-uid">10360425</article-id>
              <article-id pub-id-type="pmid">37474169</article-id>
              <article-id pub-id-type="pmid">37474169</article-id>
              <article-id pub-id-type="publisher-id">bmjopen-2022-071395</article-id>
              <article-id pub-id-type="doi">10.1136/bmjopen-2022-071395</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Diabetes and Endocrinology</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                  <subject>1843</subject>
                </subj-group>
                <series-title>Protocol</series-title>
              </article-categories>
              <title-group>
                <article-title>Manchester Intermittent and Daily diet Type 1 Diabetes App Study (MIDDAS-Type 1): protocol for a randomised feasibility trial of an intermittent and continuous low-energy diet in patients with type 1 diabetes and overweight and obesity</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-76578770" contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7668-7860</contrib-id>
                  <name>
                    <surname>McDiarmid</surname>
                    <given-names>Sarah</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-51215282" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9761-3089</contrib-id>
                  <name>
                    <surname>Harvie</surname>
                    <given-names>Michelle</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-77319429" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5756-397X</contrib-id>
                  <name>
                    <surname>Aglan</surname>
                    <given-names>Azza</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-104169078" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9944-8697</contrib-id>
                  <name>
                    <surname>Winterbottom</surname>
                    <given-names>Hannah</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-104169157" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6362-9883</contrib-id>
                  <name>
                    <surname>Mubita</surname>
                    <given-names>Womba</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-77319484" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9823-0725</contrib-id>
                  <name>
                    <surname>Hulme</surname>
                    <given-names>Amanda</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-104169228" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6366-9324</contrib-id>
                  <name>
                    <surname>Davies</surname>
                    <given-names>Jane</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib id="author-104169256" contrib-type="author">
                  <name>
                    <surname>Yates</surname>
                    <given-names>James</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib id="author-91794582" contrib-type="author">
                  <name>
                    <surname>Krizak</surname>
                    <given-names>Suzanne</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib id="author-104169322" contrib-type="author">
                  <name>
                    <surname>Perry</surname>
                    <given-names>Diane</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib id="author-77319537" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5681-2698</contrib-id>
                  <name>
                    <surname>Issa</surname>
                    <given-names>Basil G</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution content-type="department">Research Dietitians</institution>, <institution specific-use="Ringgold_5293">Manchester University NHS Foundation Trust</institution>, <addr-line content-type="city">Manchester</addr-line>, <country>UK</country></aff>
              <aff id="aff2"><label>2</label><institution content-type="department">The Prevent Breast Cancer Research Unit Research Dietitians</institution>, <institution specific-use="Ringgold_5293">Manchester University NHS Foundation Trust</institution>, <addr-line content-type="city">Manchester</addr-line>, <country>UK</country></aff>
              <aff id="aff3"><label>3</label><institution specific-use="Ringgold_9022">Greater Manchester Mental Health NHS Foundation Trust</institution>, <addr-line content-type="city">Manchester</addr-line>, <country>UK</country></aff>
              <aff id="aff4"><label>4</label><institution content-type="department">Department of Endocrinology and Diabetes</institution>, <institution specific-use="Ringgold_5293">Manchester University NHS Foundation Trust</institution>, <addr-line content-type="city">Manchester</addr-line>, <country>UK</country></aff>
              <aff id="aff5"><label>5</label><institution specific-use="Ringgold_5293">Manchester University NHS Foundation Trust</institution>, <addr-line content-type="city">Manchester</addr-line>, <country>UK</country></aff>
              <aff id="aff6"><label>6</label><institution content-type="department">Patient Representative</institution>, <institution specific-use="Ringgold_5293">Manchester University NHS Foundation Trust</institution>, <addr-line content-type="city">Manchester</addr-line>, <country>UK</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Sarah McDiarmid; <email>sarahmcdiarmid@nhs.net</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>20</day>
                <month>7</month>
                <year>2023</year>
              </pub-date>
              <volume>13</volume>
              <issue>7</issue>
              <elocation-id>e071395</elocation-id>
              <history>
                <date date-type="received">
                  <day>03</day>
                  <month>1</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>21</day>
                  <month>6</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <ali:free_to_read/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2023-07-20">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="bmjopen-2022-071395.pdf"/>
              <self-uri content-type="reviewers-comments-pdf" xlink:href="bmjopen-2022-071395.reviewer_comments.pdf"/>
              <self-uri content-type="draft-revisions-pdf" xlink:href="bmjopen-2022-071395.draft_revisions.pdf"/>
              <abstract>
                <sec>
                  <title>Introduction</title>
                  <p>Rising levels of overweight and obesity among people with type 1 diabetes (T1D) contribute to insulin resistance, dyslipidaemia, retinopathy, cardiometabolic complications and psychological morbidity. Continuous low-energy diets (CLED) providing approximately 800 kcal (3347 kJ)/day can produce significant weight loss in type 2 diabetes, and intermittent low-energy diets (ILED) may be an alternative. The Manchester Intermittent and Daily diet Type 1 Diabetes App Study (MIDDAS-Type 1) aims to assess the safety, acceptability and feasibility of remotely delivered ILED and CLED programmes for people with T1D and overweight and obesity.</p>
                </sec>
                <sec>
                  <title>Methods and analysis</title>
                  <p>Twelve participants with T1D and body mass index ≥27.5 kg/m<sup>2</sup> (≥25 kg/m<sup>2</sup> in high-risk ethnic minorities) recruited from an National Health Service (NHS) trust and research register in England will be randomised to a remotely delivered CLED (n=6) or ILED (n=6) for 12 weeks. The CLED includes a daily Optifast 850 kcal (3556 kJ) 75 g carbohydrate formula diet. The ILED includes 2 days/week of Optifast and 5 days of a portion-controlled Mediterranean diet (170–250 g carbohydrate/day). Both groups will receive matched high-frequency remote support from a dietitian, nurse and psychologist via telephone and/or the Oviva app. The primary outcome will assess safety (occurrence of severe hypoglycaemia, ketonaemia, ketoacidosis and time above and below target blood glucose). Secondary outcomes include study uptake, retention, dietary adherence, acceptability, intervention delivery fidelity and potential efficacy in relation to change in weight, insulin requirements, glycated haemoglobin, lipids, insulin resistance (estimated glucose disposal rate) and quality of life. Participants will be invited for optional repeat measurements at 52 weeks.</p>
                </sec>
                <sec>
                  <title>Ethics and dissemination</title>
                  <p>The trial protocol (V4.0/08.06.2022) was granted ethical approval by Cambridge East Research Ethics Committee (Ref: 21/EE/0014). The study will inform progression to a full-scale randomised controlled trial to test the efficacy of these programmes for patients with T1D and overweight and obesity.</p>
                </sec>
                <sec>
                  <title>Trial registration number</title>
                  <p><ext-link xlink:href="NCT04674384" ext-link-type="ClinicalTrials.gov" specific-use="clinicaltrial pre-results">NCT04674384</ext-link>; Pre-results.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>diabetes &amp; endocrinology</kwd>
                <kwd>nutrition &amp; dietetics</kwd>
                <kwd>clinical trials</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution>Manchester Foundation Trust Diabetes and Endocrinology Research endowment fund</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>N/A</award-id>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>
                    <institution-wrap>
                      <institution>Manchester Foundation Trust Charity and National Institute for Health Research Applied Research Collaboration Greater Manchester (ARC-GM)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>G72048</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text id="BX1" position="float">
              <caption>
                <title>STRENGTHS AND LIMITATIONS OF THIS STUDY</title>
              </caption>
              <list list-type="bullet">
                <list-item>
                  <p>This study addresses the unmet challenge of helping people with type 1 diabetes (T1D) and overweight and obesity lose weight safely.</p>
                </list-item>
                <list-item>
                  <p>To the best of our knowledge, this is the first study to trial continuous low-energy diet among people with T1D and overweight and obesity.</p>
                </list-item>
                <list-item>
                  <p>This study will add to the limited data on the safety and potential efficacy of intermittent low-energy diets in people with T1D and overweight and obesity.</p>
                </list-item>
                <list-item>
                  <p>Limitations include the small sample size, the diets are not isocaloric over the 12-week trial period and the lack of control group.</p>
                </list-item>
              </list>
            </boxed-text>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <sec id="s1-1">
                <title>Background</title>
                <p>There are approximately 400 000 people with type 1 diabetes (T1D) in the United Kingdom, with rates increasing by 4% annually.<xref rid="R1" ref-type="bibr">1</xref> T1D is associated with a healthy bodyweight; however, overweight and obesity is becoming increasingly common in this population due, in part, to modern more intensive approaches to manage hyperglycaemia with higher daily doses of insulin, as evidenced by the Diabetes Control and Complications Trial, and other studies.<xref rid="R2" ref-type="bibr">2 3</xref> The prevalence of obesity (body mass index (BMI) ≥30 kg/m<sup>2</sup>) in adults with T1D from the Pittsburgh Epidemiology of Diabetes Complications Study increased from 3.4% at baseline (1986–1988) to 22.7% (2004–2007).<xref rid="R4" ref-type="bibr">4</xref> This increase was greater in the group randomised to intensive therapy from 1% at baseline (1983–1989) to 31% in 2005. These increases were not associated with an ageing cohort and occurred faster than the general population. An Austrian health survey found 15 771 patients with T1D had comparable rates of overweight and obesity compared with the general population.<xref rid="R5" ref-type="bibr">5</xref> UK data from the Scottish Registry Linkage Study found rates of overweight and obesity in people with T1D from 2005 to 2007 were similar to the general population in women (27.5% and 27.6%, respectively) and lower in men (22.8% and 26.9%, respectively).<xref rid="R6" ref-type="bibr">6</xref> T1D and overweight and obesity contribute to insulin resistance, dyslipidaemia, non-alcoholic fatty liver disease, retinopathy, cardiometabolic complications and psychological morbidity.<xref rid="R7" ref-type="bibr">7 8</xref></p>
                <p>The nutritional management of type 2 diabetes (T2D) and overweight and obesity has been well researched.<xref rid="R9" ref-type="bibr">9</xref> In contrast, there is little research on weight management in T1D. Challenges in T1D include fear of hypoglycaemia and the burden of increased glucose monitoring and insulin adjustment alongside the energy restriction and increased physical activity required for weight loss.</p>
                <p>Few randomised controlled trials (RCTs) have evaluated dietary approaches to assist weight loss in T1D. One 6-month study (n=28) of modestly energy restricted (10%–20%) low-fat or Mediterranean diets resulted in little weight loss, with non-significant differences in BMI between the groups (−0.7 kg/m<sup>2</sup> and −1.1 kg/m<sup>2</sup>, respectively).<xref rid="R10" ref-type="bibr">10</xref> Modest weight loss (~2 kg) has also been reported in studies looking at the impact of low-carbohydrate diets (50–130 g carbohydrate/day) on glycaemic control and cardiovascular risk factors in patients with T1D.<xref rid="R11" ref-type="bibr">11 12</xref></p>
              </sec>
              <sec id="s1-2">
                <title>Continuous and intermittent low-energy diets</title>
                <p>Continuous and intermittent low-energy diets (LED) are popular weight management diets which been widely studied and publicised for the management of T2D. Formula-based continuous low-energy diets (CLED) (800 kcal (3347 kJ)/day for 12–20 weeks) have been shown to achieve large weight loss and remission (≥10 kg weight loss in 81% of participants and 46% diabetes remission at 12-month follow-up).<xref rid="R13" ref-type="bibr">13</xref> Our Manchester Intermittent versus Daily Diet App Study (MIDDAS) RCT in people with T2D reported that a formula-based intermittent low-energy diet (ILED) (820 kcal (3430 kJ) 2 days/week) for 28 weeks was as effective for weight and glycated haemoglobin (HbA1c) reduction as an isoenergetic formula-based CLED (820 kcal (3430 kJ)/day 7 days/week) for 8 weeks; however, diabetes medication reduction was greater in the CLED group.<xref rid="R14" ref-type="bibr">14</xref></p>
                <p>Patients with T1D attending our clinics have been asking for advice on ILED and CLED. However, there is currently little evidence of the safety or potential efficacy of these diets in patients with T1D.</p>
                <p>A recent pilot randomised trial among patients with T1D and obesity (n=10) demonstrated the safety and feasibility of a formula ILED (600 kcal (2510 kJ) and 60 g carbohydrate/day for 2 consecutive days/week and eating to appetite on 5 days) and daily modest energy restriction (around 1500–2000 kcal (6276–8368 kJ) and 200–275 g carbohydrate/day) for 12 weeks. There were no adverse events (AEs) during the study, and rates of hypoglycaemia were unchanged from baseline. Body weight reduced (p&lt;0.05) in both ILED median (IQR) −7.0% (IQR: −5.2%, −8.0%) and the daily dieting group −3.9% (IQR:−1.0%, −11.1%).<xref rid="R15" ref-type="bibr">15</xref></p>
                <p>The safety, acceptability, feasibility and efficacy of CLED (800 kcal (3347 kJ)/day) in T1D is not established. Patients with T1D may be at risk of diabetic ketoacidosis (DKA), a potentially life-threatening condition as well as severe hypoglycaemia with a CLED. No studies have tested CLED compared with ILED in patients with overweight and obesity and T1D.</p>
              </sec>
              <sec id="s1-3">
                <title>Remote multidisciplinary support</title>
                <p>The Manchester Intermittent and Daily diet Type 1 Diabetes App Study (MIDDAS-Type 1) will incorporate high-frequency remote follow-up by a multidisciplinary team (MDT) via telephone and/or the Oviva smartphone app which facilitates messaging, group interaction and self-monitoring of weight, diet, blood pressure (BP) and physical activity.<xref rid="R16" ref-type="bibr">16</xref> High-frequency remote follow-up has been shown to enhance adherence, and to be equivalent to face-to-face care (matched for frequency),<xref rid="R17" ref-type="bibr">17</xref> or superior to low-frequency face-to-face care in weight management interventions.<xref rid="R18" ref-type="bibr">18</xref> Remote follow-up also reduces participant burden to attend face-to-face appointments. Participants will use the Freestyle Libre flash glucose monitoring system<xref rid="R19" ref-type="bibr">19</xref> so that the MDT can monitor glucose and ketones remotely.</p>
              </sec>
              <sec id="s1-4">
                <title>Aims of this study</title>
                <p>MIDDAS-Type 1 will assess the safety, acceptability and feasibility of remotely supported ILED (850 kcal (3556 kJ) and 75 g carbohydrate 2 days/week) and CLED (850 kcal (3556 kJ) and 75 g carbohydrate daily) programmes for 12 weeks in people with T1D and overweight and obesity.</p>
                <p>If the feasibility trial achieves criterion on safety, recruitment, retention and adherence, then progression to a pilot RCT will be considered. This could inform the use of LEDs to help people with T1D and obesity lose weight, improve their metabolic status and reduce the risk of cardiovascular and other physical and mental comorbidities associated with T1D.</p>
              </sec>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods and analysis</title>
              <p>Standard Protocol Items: Recommendations for Intervention Trials (SPIRIT) and Template for Intervention Description and Replication (TIDieR) reporting guidelines were used.<xref rid="R20" ref-type="bibr">20</xref></p>
              <sec id="s2-1">
                <title>Design and setting</title>
                <p>MIDDAS-Type 1 is a randomised feasibility trial that will be performed in patients with T1D and overweight and obesity, recruited from an NHS hospital trust and NHS-supported voluntary research register in England. Each participant will be enrolled for 14–16 weeks from randomisation to final follow-up including a 2-week ‘run-in’ period and 12-week intervention. Participants will be invited to attend trial visits at Manchester University NHS Foundation Trust (MFT), United Kingdom. Participants will receive follow-up support from an MDT via telephone and/or the Oviva smartphone app.</p>
              </sec>
              <sec id="s2-2">
                <title>Recruitment</title>
                <p>Potentially eligible participants will be recruited to the study via:</p>
                <list list-type="order">
                  <list-item>
                    <p>Poster displays or during routine clinical contacts at MFT.</p>
                  </list-item>
                  <list-item>
                    <p>All patients with T1D (n=670) on the ‘Help BEAT Diabetes’ volunteer database (hosted by the NIHR Clinical Research Network for Greater Manchester: <ext-link xlink:href="https://www.researchforthefuture.org/diabetes/" ext-link-type="uri">https://www.researchforthefuture.org/diabetes/</ext-link>) will be invited by post/email to check that they meet the eligibility criteria for the trial and to contact the trial team if they are interested.</p>
                  </list-item>
                </list>
                <p>Participants will be provided with an information sheet about the trial to help them decide if they wish to take part.</p>
              </sec>
              <sec id="s2-3">
                <title>Eligibility criteria</title>
                <p>The eligibility criteria are presented in <xref rid="B1" ref-type="boxed-text">box 1</xref>.</p>
                <boxed-text id="B1" position="float">
                  <label>Box 1</label>
                  <caption>
                    <title>Eligibility criteria</title>
                  </caption>
                  <sec>
                    <title>Inclusion criteria</title>
                    <list list-type="bullet">
                      <list-item>
                        <p>Willing and able to provide written informed consent.</p>
                      </list-item>
                      <list-item>
                        <p>Male or female aged 18–70 years.</p>
                      </list-item>
                      <list-item>
                        <p>Diagnosed with T1D for 12 months or longer.</p>
                      </list-item>
                      <list-item>
                        <p>Multiple daily injection or continuous subcutaneous insulin infusion.</p>
                      </list-item>
                      <list-item>
                        <p>HbA1c 48–108 mmol/mol (venous blood sample).</p>
                      </list-item>
                      <list-item>
                        <p>BMI ≥27.5 kg/m<sup>2</sup> and &lt;50 kg/m<sup>2</sup> or ≥25 kg/m<sup>2</sup> and &lt;50 kg/m<sup>2</sup> in high-risk minority ethnic groups, that is, South Asian, black African and African Caribbean.</p>
                      </list-item>
                      <list-item>
                        <p>Completed Dose Adjustment For Normal Eating education<xref rid="R21" ref-type="bibr">21</xref> or equivalent structured education course for T1D.</p>
                      </list-item>
                      <list-item>
                        <p>Access to a Freestyle Libre 2 handset and sensors.<xref rid="R19" ref-type="bibr">19</xref></p>
                      </list-item>
                      <list-item>
                        <p>Access to and ability to use the Oviva app<xref rid="R16" ref-type="bibr">16</xref> and/or a telephone.</p>
                      </list-item>
                      <list-item>
                        <p>Willing to be randomised to a formula-based ILED or CLED (having tested the products).</p>
                      </list-item>
                    </list>
                  </sec>
                  <sec>
                    <title>Exclusion criteria</title>
                    <list list-type="bullet">
                      <list-item>
                        <p>Evidence of severe hypoglycaemia in the last 12 months (more than one episode requiring third-party assistance) or hypoglycaemia unawareness.</p>
                      </list-item>
                      <list-item>
                        <p>Routine HbA1c ≥108 mmol/mol during the last 3 months.</p>
                      </list-item>
                      <list-item>
                        <p>Unstable retinopathy, or grade R2 or later, or no retinopathy screen within last 12 months.</p>
                      </list-item>
                      <list-item>
                        <p>Current treatment with weight loss medications Orlistat or a glucagon-like-peptide-1 or a sodium-glucose cotransporter-2 inhibitor.</p>
                      </list-item>
                      <list-item>
                        <p>Diagnosed gastroparesis.</p>
                      </list-item>
                      <list-item>
                        <p>Pregnant/considering pregnancy.</p>
                      </list-item>
                      <list-item>
                        <p>Prior bariatric surgery.</p>
                      </list-item>
                      <list-item>
                        <p>Unintentional weight loss ≥5 kg within last 6 months.</p>
                      </list-item>
                      <list-item>
                        <p>Learning difficulties, lacking capacity or unable to understand English.</p>
                      </list-item>
                      <list-item>
                        <p>Known sensitivity to Optifast ingredients.</p>
                      </list-item>
                      <list-item>
                        <p>Diagnosed eating disorder or severe binge eating or very low eating self-efficacy as assessed by the following questionnaires: Binge Eating Scale<xref rid="R22" ref-type="bibr">22</xref> (score ≥27) and Weight Efficacy Lifestyle Questionnaire Short Form<xref rid="R23" ref-type="bibr">23</xref> (score ≤35).</p>
                      </list-item>
                      <list-item>
                        <p>Severe anxiety or depression as assessed by Generalised Anxiety Disorder Scale<xref rid="R24" ref-type="bibr">24</xref> (score ≥15) and Patient Health Questionnaire-9<xref rid="R25" ref-type="bibr">25</xref> (score ≥15).</p>
                      </list-item>
                      <list-item>
                        <p>Hazardous or harmful drinking as indicated by Alcohol Use Disorders Identification Test<xref rid="R26" ref-type="bibr">26</xref> (score ≥16).</p>
                      </list-item>
                      <list-item>
                        <p>Medications associated with weight gain, that is, lithium, antipsychotics or other psychotropic medications.</p>
                      </list-item>
                      <list-item>
                        <p>Steroids.</p>
                      </list-item>
                      <list-item>
                        <p>Current treatment with an anticoagulant.</p>
                      </list-item>
                      <list-item>
                        <p>Participants with severe loss of renal function (estimated glomerular filtration rate &lt;30 mL/min/1.73 m<sup>2</sup>).</p>
                      </list-item>
                      <list-item>
                        <p>Participants with psychiatric or physical comorbidity or scheduled for major surgery, which could compromise their safety or adherence to the study.</p>
                      </list-item>
                      <list-item>
                        <p>Current participation in other weight loss/diabetes research trials.</p>
                      </list-item>
                      <list-item>
                        <p>Unsafe use of the Freestyle Libre/insulin adjustment principles or inadequate capillary blood glucose and ketone testing during the ‘run-in’ period.</p>
                      </list-item>
                    </list>
                    <p>BMI, body mass index; CLED, continuous low-energy diet; HbA1c, glycated haemoglobin; ILED, intermittent low-energy diet; T1D, type 1 diabetes.</p>
                  </sec>
                </boxed-text>
              </sec>
              <sec id="s2-4">
                <title>Participant flow</title>
                <p>Participant flow through the study is outlined in <xref rid="F1" ref-type="fig">figure 1</xref>.</p>
                <fig position="float" id="F1">
                  <label>Figure 1</label>
                  <caption>
                    <p>Participant flow through the study.<sup>1</sup>Urine pregnancy test where required. <sup>2</sup>Body composition includes percentage body fat and fat-free mass. ADDQoL, Audit of Diabetes Dependent Quality of Life;<xref rid="R35" ref-type="bibr">35</xref> AUDIT, Alcohol Use Disorders Identification Test;<xref rid="R39" ref-type="bibr">39</xref> BES, Binge Eating Scale;<xref rid="R38" ref-type="bibr">38</xref> BMI, body mass index; BP, blood pressure; DSN, diabetes specialist nurse; eGDR, estimated glucose disposal rate; eGFR, estimated glomerular filtration rate; GAD-7, Generalised Anxiety Disorder Scale;<xref rid="R30" ref-type="bibr">30</xref> HbA1c, glycated haemoglobin; PHQ-9, Patient Health Questionnaire-9;<xref rid="R31" ref-type="bibr">31</xref> S-PAQ, Scottish Physical Activity Questionnaire;<xref rid="R36" ref-type="bibr">36</xref> WEL-SF, Weight Efficacy Lifestyle Questionnaire Short Form.<xref rid="R29" ref-type="bibr">29</xref></p>
                  </caption>
                  <graphic xlink:href="bmjopen-2022-071395f01" position="float"/>
                </fig>
                <p>Informed consent will be obtained by a trial research nurse at the screening visit.</p>
                <p>Provisionally eligible participants will commence a 2-week ‘run-in’ period, as described below:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Participants will follow their normal diet, but will sample the Optifast (Néstle Health Science, United Kingdom) meal replacement shakes to establish their preferred flavours and an appropriate bolus insulin dose per shake. Participants will be discouraged from undertaking a full low energy day until they start the diet.</p>
                  </list-item>
                  <list-item>
                    <p>Key insulin adjustment principles will be reinforced in a remote group/1–1 education session with the diabetes specialist nurse (DSN) and diabetes dietitian.</p>
                  </list-item>
                  <list-item>
                    <p>Trial the Oviva app used to communicate with the trial team (optional).</p>
                  </list-item>
                </list>
                <p>At the end of the ‘run-in’ period, the participant will attend their ‘Baseline Visit’:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>The MDT will assess adherence with the trial protocol including capillary blood glucose and ketone testing, safe insulin adjustment and their suitability for the trial.</p>
                  </list-item>
                  <list-item>
                    <p>Eligible participants will be randomised to ILED or CLED.</p>
                  </list-item>
                </list>
                <p>All participants will be invited to attend follow-up visits at MFT with a research nurse for a repeat of clinical measurements in weeks 4, 8 and 12.</p>
              </sec>
              <sec id="s2-5">
                <title>Randomisation and blinding</title>
                <p>Eligible participants will be randomised 1:1 to ILED or CLED using a sealed envelope process by the research dietitian.<xref rid="R21" ref-type="bibr">21</xref> No stratification will be used given the small sample size.</p>
                <p>Participants and clinicians will not be blinded to the treatment allocation. Laboratory results will be assessed by blinded independent laboratory staff. Analysis and interpretation of the results will be conducted by a member of the research team independent of the intervention and blinded to group allocation.</p>
              </sec>
              <sec id="s2-6">
                <title>Interventions</title>
                <p><xref rid="F1" ref-type="fig">Figure 1</xref> includes a summary of the two dietary programmes.</p>
                <sec id="s2-6-1">
                  <title>CLED programme</title>
                  <p>Participants will be asked to follow the Optifast LED 7 days/week for 12 weeks providing approximately 850 kcal (3556 kJ) and 75 g carbohydrate/day. The diet consists of three Optifast shakes/soups (216 kcal (904 kJ) and 19 g carbohydrate/sachet) plus 7×80 g portions of non-starchy vegetables (approximately 120 kcal (502 kJ) and 18 g carbohydrate), one dessertspoon of oil (80 kcal (335 kJ)) and 2–2.5 L of calorie-free fluids. Participants will be asked to avoid alcohol and excessive caffeine to minimise the risk of dehydration.</p>
                </sec>
                <sec id="s2-6-2">
                  <title>ILED programme</title>
                  <p>Participants will be asked to follow the Optifast LED on 2 consecutive days/week plus 5 days of a portion-controlled Mediterranean diet to achieve at least a 25% energy restriction across the week. The maximum dietary intake allowed on each of the Mediterranean diet days will be, for example, 2200 kcal (9204 kJ)/day for a man and 1800 kcal (7531 kJ)/day for a woman aged 50 years old with a BMI of 35. The diet prescription on the Mediterranean days is personalised to each participant. The estimation is based on the Mifflin equation,<xref rid="R22" ref-type="bibr">22</xref> multiplied by participants’ self-reported physical activity levels.<xref rid="R23" ref-type="bibr">23</xref> The Mediterranean diet used described previously by Harvie <italic toggle="yes">et al</italic><xref rid="R24" ref-type="bibr">24</xref> is relatively high in protein (25% energy) with moderate carbohydrate (45% energy from low glycaemic load wholegrain carbohydrates) and moderate fat (30% energy from fat: 15% monounsaturated, 8% polyunsaturated and 7% saturated fatty acids) and limits alcohol to &lt;10 units/week.</p>
                  <p>The Mediterranean diet described contains approximately 150–300 g carbohydrate/day depending on an individual’s energy requirements. Energy-controlled Mediterranean diets are considered optimum for reducing weight, BP and improving lipid profiles<xref rid="R25" ref-type="bibr">25 26</xref> and may reduce the incidence of cardiovascular disease in people with T1D.<xref rid="R27" ref-type="bibr">27</xref></p>
                  <p>Participants in both groups who are unable to tolerate Optifast during the 12-week intervention will be offered a food-based LED with a similar macronutrient profile to Optifast. This will comprise 250 g of lean protein foods (eg, lean meat, fish, eggs and vegetarian proteins), five portions of non-starchy vegetables, three portions of low-fat dairy (eg, 200 mL milk is one portion), one portion of unsaturated fat (eg, small handful nuts), one portion of fruit, and one carbohydrate portion (eg, slice of bread).</p>
                </sec>
                <sec id="s2-6-3">
                  <title>Physical activity</title>
                  <p>Participants will be asked to maintain their current activity levels to simplify glucose management and to help isolate the effects of the diets on weight and HbA1c. However, participants will be advised to avoid vigorous activity until they are familiar with the effect of their allocated LED on blood glucose. Participants will be advised to use principles from their previous diabetes education course, for example, Dose Adjustment For Normal Eating (DAFNE)<xref rid="R28" ref-type="bibr">28</xref> on managing insulin with physical activity. They will be encouraged to plan physical activity so that they can adjust their insulin prior to physical activity rather than relying on additional carbohydrate. All participants will be encouraged to monitor their blood glucose before, during and after physical activity and carry hypoglycaemia treatment.</p>
                </sec>
                <sec id="s2-6-4">
                  <title>Behavioural support</title>
                  <p>Both groups will receive matched frequency of behavioural support from an MDT including a diabetes specialist dietitian, DSN and psychologist (if eligible) (<xref rid="F1" ref-type="fig">figure 1</xref>).</p>
                  <p>Participants will be invited to communicate with the MDT via the Oviva smartphone app. The app facilitates messaging, and self-monitoring of weight, diet, BP and physical activity.</p>
                  <p>Participants will be invited to participate in group messaging with other participants in their allocated diet group. If participants choose not to use the app, then scheduled follow-up will be done by telephone.</p>
                  <p>The support provided by the MDT to both groups is detailed in the <xref rid="SP1 SP2" ref-type="supplementary-material">online supplemental table</xref>.</p>
                  <supplementary-material id="SP1" position="float" content-type="local-data">
                    <object-id pub-id-type="doi">10.1136/bmjopen-2022-071395.supp1</object-id>
                    <label>Supplementary data</label>
                    <p>
                      <inline-supplementary-material id="SS1" xlink:href="bmjopen-2022-071395supp001.pdf" content-type="local-data"/>
                    </p>
                  </supplementary-material>
                  <supplementary-material id="SP2" position="float" content-type="local-data">
                    <object-id pub-id-type="doi">10.1136/bmjopen-2022-071395.supp2</object-id>
                    <label>Supplementary data</label>
                    <p>
                      <inline-supplementary-material id="SS2" xlink:href="bmjopen-2022-071395supp002.pdf" content-type="local-data"/>
                    </p>
                  </supplementary-material>
                  <p>The diabetes dietitian will provide education on the LEDs and how to use the Oviva app, either by telephone or face to face at the baseline visit. All participants will be provided with written support materials, including recipes and meal plans. The DSN will provide education on the Freestyle Libre<xref rid="R19" ref-type="bibr">19</xref> and the study requirements around self-monitoring of blood glucose/ketones and medication adjustment face to face at the screening and baseline visits.</p>
                  <p>Enhanced psychology support from the trial psychologist will be available for participants with questionnaire scores indicating low self-efficacy (score 36–45 on Weight Efficacy Lifestyle Questionnaire Short Form (WEL-SF)<xref rid="R29" ref-type="bibr">29</xref>), moderate anxiety (score 10–14 on Generalised Anxiety Disorder Scale (GAD-7)<xref rid="R30" ref-type="bibr">30</xref>) or moderate depression (score 10–14 on Patient Health Questionnaire-9 (PHQ-9)<xref rid="R31" ref-type="bibr">31</xref>). GAD-7 and PHQ-9 will be repeated at the week 4 and 8 appointments to check the well-being of participants while on the trial. Psychological intervention will be informed by cognitive–behavioural therapy, Motivational Interviewing and Acceptance and Commitment Therapy.<xref rid="R32" ref-type="bibr">32</xref></p>
                  <p>All members of the MDT will be trained in motivational interviewing techniques (a well-established model of supporting behavioural change with proven efficacy in facilitating weight loss), to support dietary behavioural changes. Both programmes will use behaviour change techniques such as problem solving and feedback on behaviour, identified as being effective at reducing HbA1c.<xref rid="R33" ref-type="bibr">33</xref> The programmes will also use established behaviour change techniques, such as goal setting and self-monitoring.<xref rid="R34" ref-type="bibr">34</xref></p>
                </sec>
                <sec id="s2-6-5">
                  <title>Self-monitoring of glucose, ketones, BP and weight</title>
                  <p>Participants will sign a treatment contract to adhere to flash and capillary glucose, ketone and BP monitoring plans (see <xref rid="SP1" ref-type="supplementary-material">online supplemental appendix</xref>) using the Libre, and a BP monitor provided by the study team. Glucose and ketone data will be visible to the study team on the LibreView website.<xref rid="R19" ref-type="bibr">19</xref></p>
                  <p>Participants will be asked to report their BP fortnightly and their weight weekly via the Oviva app and/or by telephone.</p>
                  <p>Participants will be advised to report promptly via telephone and/or the Oviva app if they experience any of the following:</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>Severe hypoglycaemia, that is, blood glucose &lt;3.0 mmol/L or nocturnal hypoglycaemia &lt;3.0 mmol/L or hypoglycaemia requiring third-party assistance. Participants will also be asked to record episodes of hypoglycaemia (&lt;4.0 mmol/L) in a diary.</p>
                    </list-item>
                    <list-item>
                      <p>Blood glucose &gt;15.0 mmol/L on two consecutive occasions.</p>
                    </list-item>
                    <list-item>
                      <p>Blood ketones (β-hydroxybutyrate) &gt;1.0 mmol/L.</p>
                    </list-item>
                    <list-item>
                      <p>Systolic BP &gt;165 mm Hg.</p>
                    </list-item>
                  </list>
                </sec>
                <sec id="s2-6-6">
                  <title>Diabetes and antihypertensive medication management</title>
                  <p>The trial diabetes and antihypertensive medication management plans are detailed in the <xref rid="SP1" ref-type="supplementary-material">online supplemental appendix</xref>. The diabetes medication management plan for multiple daily injection and continuous subcutaneous insulin infusion has been adapted from a protocol tested in a recent ILED trial of people with T1D<xref rid="R15" ref-type="bibr">15</xref> and DAFNE insulin dose adjustment principles.<xref rid="R28" ref-type="bibr">28</xref> When a participant commences their allocated diet, basal insulin will be reduced by 50% on low-energy days, and 10% on Mediterranean days. Participants’ existing insulin to carbohydrate ratios and sensitivity factors will continue. Participants on metformin will continue with their existing dose when they commence the trial. Insulin will be adjusted after baseline according to the diabetes medication management plan and clinical need. All changes to medications will be agreed with the trial doctor. General practitioners (GPs) will be notified by letter of the enrolment of their patients and changes to medications.</p>
                </sec>
                <sec id="s2-6-7">
                  <title>End of intervention</title>
                  <p>At week 12, participants’ care will revert to their usual diabetes MDT. The trial dietitian will provide dietary advice to support their future weight loss plans but will advise against continuing a LED without the support of a medical team. The trial diabetes nurse will provide a final review of blood glucose and advise on appropriate medication adjustment. Participants’ GPs and diabetes teams will be informed accordingly.</p>
                </sec>
              </sec>
              <sec id="s2-7">
                <title>Outcomes</title>
                <sec id="s2-7-1">
                  <title>Overall aim</title>
                  <p>The aim of the feasibility trial is to assess the safety, acceptability and feasibility of remotely supported ILED and CLED programmes for 12 weeks in people with T1D and obesity.</p>
                </sec>
                <sec id="s2-7-2">
                  <title>Primary outcome</title>
                  <sec id="s2-7-2-1">
                    <title>Safety</title>
                    <list list-type="order">
                      <list-item>
                        <p>Episodes of severe hypoglycaemia, that is, capillary blood glucose &lt;3.0 mmol/L or requiring third-party assistance or any episodes of nocturnal hypoglycaemia&lt;3.0 mmol/L.</p>
                      </list-item>
                      <list-item>
                        <p>Time spent in target (3.9–10 mmol/L), below target (&lt;3.9 mmol/L and&lt;3.0 mmol/L) and above target (&gt;10 mmol/L) on the Freestyle Libre over 12 weeks.</p>
                      </list-item>
                      <list-item>
                        <p>Episodes of DKA (as defined by MFT guidelines: ketonaemia &gt;3.0 mmol/L or significant ketonuria (more than 2+ on standard urine sticks) and blood glucose &gt;11.0 mmol/L or known diabetes mellitus (type 1 or 2) and bicarbonate (HCO3<sup>−</sup>) &lt;15.0 mmol/L and/or venous pH &lt;7.3) and blood ketone β-hydroxybutyrate levels above 1.0 mmol/L.</p>
                      </list-item>
                    </list>
                    <p>Occurrence of serious AEs deemed potentially related to the dietary programmes, that is, outcomes requiring hospitalisation.</p>
                  </sec>
                </sec>
                <sec id="s2-7-3">
                  <title>Secondary outcomes</title>
                  <list list-type="order">
                    <list-item>
                      <p>Trial uptake, that is, percentage of those invited who are eligible and interested to take part.</p>
                    </list-item>
                    <list-item>
                      <p>Retention to ILED and CLED interventions and completion of 12-week assessments.</p>
                    </list-item>
                    <list-item>
                      <p>Adherence to blood glucose and ketone monitoring.</p>
                    </list-item>
                    <list-item>
                      <p>Participant adherence to ILED and CLED including self-reported adherence to LED days, preference for face-to-face contact with the dietitian and preference for food-based versus formula-based low energy days.</p>
                    </list-item>
                    <list-item>
                      <p>Seven-day food diaries will be analysed using Nutritics nutrition analysis software to estimate energy, fat, saturated fat, carbohydrate and protein intake.</p>
                    </list-item>
                    <list-item>
                      <p>Patient evaluation of the dietary programmes using a questionnaire.</p>
                    </list-item>
                    <list-item>
                      <p>Fidelity of delivery of the dietary programmes by the MDT, that is, percentage of contacts achieved, time spent by the MDT, preference for face-to-face contact with the dietitian, and attendance at follow-up visits.</p>
                    </list-item>
                    <list-item>
                      <p>Uptake to and continued use of the Oviva app for self-monitoring and communication.</p>
                    </list-item>
                    <list-item>
                      <p>Minor adverse effects which may be associated with the dietary programmes, for example, constipation and fatigue.</p>
                    </list-item>
                  </list>
                  <sec id="s2-7-3-1">
                    <title>Changes to the following from baseline to 12 weeks in both groups</title>
                    <list list-type="order">
                      <list-item>
                        <p>Weight, body fat, fat free mass (bioelectrical impedance Tanita MC980MA), waist and hip circumference.</p>
                      </list-item>
                      <list-item>
                        <p>Doses of insulin and other diabetes medication.</p>
                      </list-item>
                      <list-item>
                        <p>HbA1c, number of hypoglycaemic (capillary blood glucose &lt;4.0 mmol/L) events, blood lipids and estimated glucose disposal rate (eGDR) as a measure of insulin resistant (see <xref rid="SP1" ref-type="supplementary-material">online supplemental appendix</xref>).</p>
                      </list-item>
                      <list-item>
                        <p>Quality of life, that is, self-efficacy (WEL-SF),<xref rid="R29" ref-type="bibr">29</xref> anxiety (GAD-7),<xref rid="R30" ref-type="bibr">30</xref> depression (PHQ-9)<xref rid="R31" ref-type="bibr">31</xref> and Audit of Diabetes-Dependent Quality of Life (ADDQoL).<xref rid="R35" ref-type="bibr">35</xref></p>
                      </list-item>
                      <list-item>
                        <p>Physical activity (Scottish Physical Activity Questionnaire (S-PAQ)).<xref rid="R36" ref-type="bibr">36</xref></p>
                      </list-item>
                      <list-item>
                        <p>Change in BP medications.</p>
                      </list-item>
                    </list>
                  </sec>
                </sec>
                <sec id="s2-7-4">
                  <title>Exploratory outcomes</title>
                  <sec id="s2-7-4-1">
                    <title>Substudy</title>
                    <p>At their week 12 visit, participants will be invited to attend and consent to a follow-up visit at MFT at 52 weeks. This will capture change in weight, body composition, waist and hip circumference, BP, HbA1c, eGDR, blood lipids and quality of life (WEL-SF,<xref rid="R29" ref-type="bibr">29</xref> GAD-7,<xref rid="R30" ref-type="bibr">30</xref> PHQ-9<xref rid="R31" ref-type="bibr">31</xref> and ADDQoL<xref rid="R35" ref-type="bibr">35</xref>) to assess the long-term impact of LEDs on people with T1D and obesity.</p>
                  </sec>
                </sec>
              </sec>
              <sec id="s2-8">
                <title>Trial progression criterion</title>
                <p>If the feasibility trial meets the following criterion, then progression to a future efficacy trial/definitive RCT will be considered:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Safety: withdrawal of ≤25% of patients with severe hypoglycaemia requiring third party assistance.</p>
                  </list-item>
                  <list-item>
                    <p>Recruitment: successful recruitment of 12 patients to the study.</p>
                  </list-item>
                  <list-item>
                    <p>Retention: ≥50%. Complete the 12-week assessments.</p>
                  </list-item>
                  <list-item>
                    <p>Adherence: &gt;50% of low energy days completed in both groups.</p>
                  </list-item>
                </list>
              </sec>
              <sec id="s2-9">
                <title>Measurements</title>
                <p><xref rid="T1" ref-type="table">Table 1</xref> is a summary of the measurements collected at each scheduled visit.</p>
                <table-wrap position="float" id="T1">
                  <label>Table 1</label>
                  <caption>
                    <p>Schedule of measurements*</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <td align="left" valign="bottom" rowspan="1" colspan="2">Enrolment</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="4">Follow-up visits</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Timepoint</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Screening visit</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Baseline visit</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Week 4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Week 8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Week 12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Week 52 (substudy)</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Enrolment:</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Informed consent</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Eligibility screen</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x†</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Randomisation</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Intervention groups:</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Intermittent low-energy diet</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="3">
                          <inline-graphic xlink:href="bmjopen-2022-071395ilf01.jpg" id="img1"/>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Continuous low-energy diet</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="3">
                          <inline-graphic xlink:href="bmjopen-2022-071395ilf02.jpg" id="img2"/>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Assessments:</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Height</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Weight</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Waist circumference</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Hip circumference</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Body composition</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Blood pressure, heart rate‡</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Urine pregnancy test</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Estimated glucose disposal rate</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>HbA1c, lipids</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Urea and electrolytes, creatinine, estimated glomerular filtration rate, liver function tests full blood count</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>BES Questionnaire</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>WEL-SF Questionnaire</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>GAD-7 Questionnaire</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>PHQ-9 Questionnaire</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>AUDIT Questionnaire</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>ADDQoL Questionnaire</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>S-PAQ Questionnaire</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Seven-day food diary</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Low-energy day diary</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Hypoglycaemia diary</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Patient Evaluation Questionnaire</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T1_FN1">
                      <p>*Questionnaire abbreviations: Binge Eating Scale (BES),<xref rid="R38" ref-type="bibr">38</xref> Weight Efficacy Lifestyle Questionnaire Short Form (WEL-SF),<xref rid="R29" ref-type="bibr">29</xref> Generalised Anxiety Disorder Scale (GAD-7),<xref rid="R30" ref-type="bibr">30</xref> Patient Health Questionnaire-9 (PHQ-9),<xref rid="R31" ref-type="bibr">31</xref> Alcohol Use Disorders Identification Test (AUDIT),<xref rid="R39" ref-type="bibr">39</xref> Audit of Diabetes Dependent Quality of Life (ADDQoL)<xref rid="R35" ref-type="bibr">35</xref> and Scottish Physical Activity Questionnaire (S-PAQ).<xref rid="R36" ref-type="bibr">36</xref></p>
                    </fn>
                    <fn id="T1_FN2">
                      <p>†Recheck of eligibility following 2-week ‘run-in’ period.</p>
                    </fn>
                    <fn id="T1_FN3">
                      <p>‡Participants will be provided with home blood pressure monitors for self-monitoring between follow-up visits. Further investigation with an echocardiogram if heart rate &lt;50 beats/minute and not on β blockers.</p>
                    </fn>
                    <fn id="T1_FN4">
                      <p>HbA1c, glycated haemoglobin.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <sec id="s2-9-1">
                  <title>Participant characteristics</title>
                  <p>Information will be collected on participants’ age, sex, ethnicity, marital status, number and age of dependents living at home, education history, employment status, index of multiple deprivation score based on their post code, relevant medical history, current medication, and smoking status.</p>
                </sec>
                <sec id="s2-9-2">
                  <title>Physical measurements</title>
                  <p>Weight and body composition will be measured using Tanita MC-980MA calibrated scales to the nearest 0.1 kg. Height will be measured using a portable stadiometer. Waist circumference will be measured halfway between the point of the lowest rib and the iliac crest, and hip circumference will be measured at the maximum circumference of the buttocks.<xref rid="R37" ref-type="bibr">37</xref> Waist and hip will be measured to the nearest 1 mm. BP will be measured with patients seated, at rest, for at least 10 min. Waist, hip and BP will be repeated on three occasions and an average taken. Assessors will be trained in accordance with departmental protocols.</p>
                </sec>
                <sec id="s2-9-3">
                  <title>Blood sample</title>
                  <p>A venous blood sample will be collected for HbA1c, lipid profile, serum urea and electrolytes, glomerular filtration rate, creatinine, liver function tests and a full blood count.</p>
                </sec>
                <sec id="s2-9-4">
                  <title>Urine pregnancy test</title>
                  <p>A urine pregnancy test will be performed in those who are able to bear children, who are sexually active, in the childbearing age group, and not using a reliable means of contraception (pill or intrauterine device).</p>
                </sec>
                <sec id="s2-9-5">
                  <title>Questionnaires</title>
                  <p>The questionnaires completed are BES,<xref rid="R38" ref-type="bibr">38</xref> WEL-SF,<xref rid="R29" ref-type="bibr">29</xref> GAD-7,<xref rid="R30" ref-type="bibr">30</xref> PHQ-9,<xref rid="R31" ref-type="bibr">31</xref> AUDIT,<xref rid="R39" ref-type="bibr">39</xref> ADDQoL<xref rid="R35" ref-type="bibr">35</xref> and S-PAQ.<xref rid="R36" ref-type="bibr">36</xref> Participants will self-report adherence to low-energy days, and episodes of hypoglycaemia (capillary blood glucose &lt;4 mmol/L) will be documented in paper diaries collected at follow-up visits. The anonymous Patient Evaluation Questionnaire at week 12 will be optional and will use Likert Scales and open questions to obtain feedback on the delivery of the ILED and CLED programmes.</p>
                </sec>
              </sec>
              <sec id="s2-10">
                <title>Retention and withdrawal</title>
                <p>Participants may withdraw from the study at their own request or at the discretion of the chief investigator. Data will be retained for use, and relevant data will be sourced from their medical records for the duration of the trial, unless they do not consent to this. Withdrawal from the study will not affect patient care.</p>
              </sec>
              <sec id="s2-11">
                <title>Adverse events</title>
                <p>All serious AEs in the 12-week study period will be recorded following Good Clinical Practice (GCP) and Health Research Authority processes. Recording of non-serious AEs which may be associated with the LED (eg, constipation, fatigue or hair loss) will be recorded using the National Cancer Institute CTCAE V.5.0,<xref rid="R40" ref-type="bibr">40</xref> when participants inform the trial team.</p>
              </sec>
              <sec id="s2-12">
                <title>Sample size and statistical analysis</title>
                <p>The target sample size is 12 participants. This was chosen pragmatically to obtain sufficient data on the safety and feasibility of an ILED and CLED in people with T1D and overweight and obesity, while balancing cost and time. With this sample size there is a high probability of seeing at least one episode of severe hypoglycaemia or DKA.</p>
                <p>This study will not undertake significance tests. Descriptive, graphical and/or basic inferential statistics of endpoints will be presented, for example, frequencies and percentages, mean and SD or median and quartiles, as appropriate. Levels of missing data will be investigated and used to inform future studies. No imputation will be used. There will be no interim analysis or stopping guidelines. A full statistical analysis plan will be prepared prior to data analysis.</p>
              </sec>
              <sec id="s2-13">
                <title>Patient and public involvement</title>
                <p>This study evolved from patients at MFT with T1D and overweight and obesity asking healthcare professionals for advice and support to follow LEDs. There will be a patient representative on the trial management group. Another patient with T1D has kindly contributed to the design of dietary resources.</p>
              </sec>
              <sec id="s2-14">
                <title>Data management</title>
                <p>Data will be recorded on hard copy and subsequently transferred to a database with ranges and programmed validation checks to aid reliable data entry. Data are held on secure servers at MFT. All trial data will be kept confidential in accordance with GCP guidelines. Participants consent at baseline to their personal data being shared with Abbott (manufacturer of the Freestyle Libre), Oviva UK Ltd (if they choose to use the smartphone app on the trial) and Nestle Health Science for home delivery of Optifast.</p>
              </sec>
              <sec id="s2-15">
                <title>Multidisciplinary team</title>
                <p>There will be a weekly MDT meeting including the chief investigator, co-investigator, DSN, diabetes dietitian and research nurses to discuss each participant, potential recruitment and to check adherence to protocol.</p>
              </sec>
              <sec id="s2-16">
                <title>Trial Management Group</title>
                <p>The Trial Management Group (TMG) will provide oversight of participant safety and data quality. It will include the chief investigator (BGI), co-investigator (MH), principal clinical psychologist (AA), trial diabetes specialist dietitians (SM, HW), trial DSNs (AS, WM) and clinical trial manager. The TMG will meet regularly to review the trial’s safety data and modify the medicine management/monitoring plans as appropriate. The trial will be stopped by the sponsor, CI or the TMG if there are concerns regarding participant safety, or for any reasons given by the Research Ethics Committee (REC). The trial is subject to inspection and audit by MFT as the trial sponsor.</p>
              </sec>
              <sec id="s2-17">
                <title>Ethics and dissemination</title>
                <p>Approval for this study has been obtained from the Cambridge East REC (ref: 21/EE/0014), and the study has been registered with ClinicalTrials.gov (identifier NCT04674384). Results will be submitted for publication in peer-review journals presented at conferences and shared with trial participants. Planned modifications to the protocol will be approved by the REC before they are adopted into the study. An audit trail of ethical amendments and documentation will be kept to allow monitoring by the research team and external regulatory bodies.</p>
              </sec>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="d64e219">
                <caption>
                  <title>Reviewer comments</title>
                </caption>
                <media xlink:href="bmjopen-2022-071395.reviewer_comments.pdf"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="d64e220">
                <caption>
                  <title>Author's
manuscript</title>
                </caption>
                <media xlink:href="bmjopen-2022-071395.draft_revisions.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>The authors would like to thank members of the MIDDAS-Type 1 patient participation panel for their advice on the participant resources that will be used in this trial; and also Catherine Fullwood for her invaluable statistical advice and Katharine Grady for recruitment via the voluntary research register ‘Research For Future’.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> BGI is the principal investigator. SM, MH, BGI and AA all contributed to the design of the study. BGI and MH provide study oversight and clinical guidance. HW and MH are responsible for delivery of the dietetic component of the study. WM is the diabetes nurse on the trial. AH, JD and WB collected patient data. SK and JY are responsible for study administration. SM, MH and BGI contributed to protocol development and achieving ethical approval. AA is responsible for the psychological intervention. DP provided patient and public involvement to the trial. SM drafted the initial manuscript. All authors critically reviewed and revised the manuscript and have read and approved the final version.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> The project and Sarah McDiarmid (Diabetes Specialist Dietitian) are partially funded by the MFT Charity and the National Institute for Health Research (NIHR) Applied Research Collaboration Greater Manchester (grant number G72048). The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The project is also partially funded by the MFT Diabetes and Endocrinology Research endowment fund. Nestlé Health Science will provide the Optifast formula-diet and Oviva UK Ltd will provide the smartphone app. The funders will have no input into the decisions regarding publication. The sponsor is MFT (Research and Innovation, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Southmoor Road, Manchester M23 9LT, UK).</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> None declared.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Patient and public involvement:</bold> Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Supplemental material:</bold> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p>
              </fn>
            </fn-group>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec>
                <title>Patient consent for publication</title>
                <p content-type="ethics-consent-to-publish">Not applicable.</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="webpage"><article-title>JDRF</article-title>. <comment>n.d.</comment><comment>Available</comment>: <uri xlink:href="https://jdrf.org.uk/information-support/about-type-1-diabetes/facts-and-figures/">https://jdrf.org.uk/information-support/about-type-1-diabetes/facts-and-figures/</uri></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nathan</surname><given-names>DM</given-names></string-name>, <string-name><surname>Zinman</surname><given-names>B</given-names></string-name>, <string-name><surname>Cleary</surname><given-names>PA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Diabetes control and complications trial, epidemiology of diabetes interventions and complications (DCCT/EDIC) research group. modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005)</article-title>. <source>Arch Intern Med</source><year>2009</year>;<volume>169</volume>:<elocation-id>1307</elocation-id>. <pub-id pub-id-type="doi">10.1001/archinternmed.2009.193</pub-id><pub-id pub-id-type="pmid">19636033</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cantley</surname><given-names>NW</given-names></string-name>, <string-name><surname>Lonnen</surname><given-names>K</given-names></string-name>, <string-name><surname>Kyrou</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The association between overweight/obesity and double diabetes in adults with type 1 diabetes; a cross-sectional study</article-title>. <source>BMC Endocr Disord</source><year>2021</year>;<volume>21</volume>:<elocation-id>187</elocation-id>. <pub-id pub-id-type="doi">10.1186/s12902-021-00851-1</pub-id><pub-id pub-id-type="pmid">34530819</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Conway</surname><given-names>B</given-names></string-name>, <string-name><surname>Miller</surname><given-names>RG</given-names></string-name>, <string-name><surname>Costacou</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Temporal patterns in overweight and obesity in type 1 diabetes</article-title>. <source>Diabet Med</source><year>2009</year>;<volume>17</volume>:<fpage>389</fpage>–<lpage>404</lpage>.</mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fellinger</surname><given-names>P</given-names></string-name>, <string-name><surname>Fuchs</surname><given-names>D</given-names></string-name>, <string-name><surname>Wolf</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Overweight and obesity in type 1 diabetes equal those of the general population</article-title>. <source>Wien Klin Wochenschr</source><year>2019</year>;<volume>131</volume>:<fpage>55</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1007/s00508-018-1434-9</pub-id><pub-id pub-id-type="pmid">30617710</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Livingstone</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Looker</surname><given-names>HC</given-names></string-name>, <string-name><surname>Hothersall</surname><given-names>EJ</given-names></string-name>, <etal>et al</etal></person-group>. <comment>n.d.</comment><article-title>Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish Registry linkage study</article-title>. <source>PLoS Med</source>;<volume>9</volume>:<elocation-id>e1001321</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001321</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Purnell</surname><given-names>JQ</given-names></string-name>, <string-name><surname>Zinman</surname><given-names>B</given-names></string-name>, <string-name><surname>Brunzell</surname><given-names>JD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and Atherosclerosis in type 1 diabetes mellitus: results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study (DCCT/EDIC) study</article-title>. <source>Circulation</source><year>2013</year>;<volume>127</volume>:<fpage>180</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.077487</pub-id><pub-id pub-id-type="pmid">23212717</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Price</surname><given-names>SA</given-names></string-name>, <string-name><surname>Gorelik</surname><given-names>A</given-names></string-name>, <string-name><surname>Fourlanos</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Obesity is associated with retinopathy and Macrovascular disease in type 1 diabetes</article-title>. <source>Obesity Research &amp; Clinical Practice</source><year>2014</year>;<volume>8</volume>:<fpage>e178</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.orcp.2013.03.007</pub-id><pub-id pub-id-type="pmid">24743014</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dyson</surname><given-names>PA</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>T</given-names></string-name>, <string-name><surname>Deakin</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Diabetes UK evidence-based nutrition guidelines for the prevention and management of diabetes</article-title>. <source>Diabet Med</source><year>2011</year>;<volume>28</volume>:<fpage>1282</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1464-5491.2011.03371.x</pub-id><pub-id pub-id-type="pmid">21699560</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fortin</surname><given-names>A</given-names></string-name>, <string-name><surname>Rabasa-Lhoret</surname><given-names>R</given-names></string-name>, <string-name><surname>Lemieux</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Comparison of a Mediterranean to a low-fat diet intervention in adults with type 1 diabetes and metabolic syndrome: A 6-month randomized trial</article-title>. <source>Nutr Metab Cardiovasc Dis</source><year>2018</year>;<volume>28</volume>:<fpage>1275</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.numecd.2018.08.005</pub-id><pub-id pub-id-type="pmid">30459054</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krebs</surname><given-names>JD</given-names></string-name>, <string-name><surname>Parry Strong</surname><given-names>A</given-names></string-name>, <string-name><surname>Cresswell</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A randomised trial of the feasibility of a low carbohydrate diet vs standard carbohydrate counting in adults with type 1 diabetes taking body weight into account</article-title>. <source>Asia Pac J Clin Nutr</source><year>2016</year>;<volume>25</volume>:<fpage>78</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.6133/apjcn.2016.25.1.11</pub-id><pub-id pub-id-type="pmid">26965765</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmidt</surname><given-names>S</given-names></string-name>, <string-name><surname>Christensen</surname><given-names>MB</given-names></string-name>, <string-name><surname>Serifovski</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Low versus high carbohydrate diet in type 1 diabetes: A 12‐Week randomized Open‐Label crossover study</article-title>. <source>Diabetes Obes Metab</source><year>2019</year>;<volume>21</volume>:<fpage>1680</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/dom.13725</pub-id><pub-id pub-id-type="pmid">30924570</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lean</surname><given-names>ME</given-names></string-name>, <string-name><surname>Leslie</surname><given-names>WS</given-names></string-name>, <string-name><surname>Barnes</surname><given-names>AC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Primary care-led weight management for remission of type 2 diabetes (direct): an open-label, cluster-randomised trial</article-title>. <source>The Lancet</source><year>2018</year>;<volume>391</volume>:<fpage>541</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(17)33102-1</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McDiarmid</surname><given-names>S</given-names></string-name>, <string-name><surname>Harvie</surname><given-names>M</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Manchester intermittent versus daily diet App study (MIDDAS): A pilot randomized controlled trial in patients with type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source><year>2022</year>;<volume>24</volume>:<fpage>432</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1111/dom.14592</pub-id><pub-id pub-id-type="pmid">34726317</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Overland</surname><given-names>J</given-names></string-name>, <string-name><surname>Toth</surname><given-names>K</given-names></string-name>, <string-name><surname>Gibson</surname><given-names>AA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The safety and efficacy of weight loss via intermittent fasting or standard daily energy restriction in adults with type 1 diabetes and overweight or obesity: A pilot study</article-title>. <source>Obesity Medicine</source><year>2018</year>;<volume>12</volume>:<fpage>13</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.obmed.2018.11.001</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="webpage"><article-title>Oviva UK</article-title>. <comment>n.d.</comment><comment>Available</comment>: <uri xlink:href="https://oviva.com/uk/en/our-programmes/type-2-diabetes-management/">https://oviva.com/uk/en/our-programmes/type-2-diabetes-management/</uri></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huntriss</surname><given-names>R</given-names></string-name>, <string-name><surname>Haines</surname><given-names>M</given-names></string-name>, <string-name><surname>Jones</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A service evaluation exploring the effectiveness of a locally commissioned tier 3 weight management programme offering Face‐To‐Face, telephone and Digital Dietetic support</article-title>. <source>Clin Obes</source><year>2021</year>;<volume>11</volume>:<elocation-id>e12444</elocation-id>. <pub-id pub-id-type="doi">10.1111/cob.12444</pub-id><pub-id pub-id-type="pmid">33600056</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Digenio</surname><given-names>AG</given-names></string-name>, <string-name><surname>Mancuso</surname><given-names>JP</given-names></string-name>, <string-name><surname>Gerber</surname><given-names>RA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial</article-title>. <source>Ann Intern Med</source><year>2009</year>;<volume>150</volume>:<fpage>255</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-150-4-200902170-00006</pub-id><pub-id pub-id-type="pmid">19221377</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="webpage"><article-title>Freestyle Libre</article-title>. <comment>n.d.</comment><comment>Available</comment>: <uri xlink:href="https://www.freestylelibre.co.uk/%20and%20https://www.libreview.com/">https://www.freestylelibre.co.uk/%20and%20https://www.libreview.com/</uri></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chan</surname><given-names>A-W</given-names></string-name>, <string-name><surname>Tetzlaff</surname><given-names>JM</given-names></string-name>, <string-name><surname>Altman</surname><given-names>DG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>SPIRIT 2013 statement: defining standard protocol items for clinical trials</article-title>. <source>Ann Intern Med</source><year>2013</year>;<volume>158</volume>:<fpage>200</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-158-3-201302050-00583</pub-id><pub-id pub-id-type="pmid">23295957</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Sealed envelope</collab></person-group>. <article-title>Randomisation and online databases for clinical trials</article-title>. <comment>n.d.</comment><comment>Available</comment>: <uri xlink:href="https://www.sealedenvelope.com/">https://www.sealedenvelope.com/</uri></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mifflin</surname><given-names>MD</given-names></string-name>, <string-name><surname>St Jeor</surname><given-names>ST</given-names></string-name>, <string-name><surname>Hill</surname><given-names>LA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A new predictive equation for resting energy expenditure in healthy individuals</article-title>. <source>Am J Clin Nutr</source><year>1990</year>;<volume>51</volume>:<fpage>241</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1093/ajcn/51.2.241</pub-id><pub-id pub-id-type="pmid">2305711</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ainsworth</surname><given-names>BE</given-names></string-name>, <string-name><surname>Haskell</surname><given-names>WL</given-names></string-name>, <string-name><surname>Herrmann</surname><given-names>SD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Compendium of physical activities: a second update of codes and MET values</article-title>. <source>Med Sci Sports Exerc</source><year>2011</year>;<volume>43</volume>:<fpage>1575</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1249/MSS.0b013e31821ece12</pub-id><pub-id pub-id-type="pmid">21681120</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harvie</surname><given-names>M</given-names></string-name>, <string-name><surname>Wright</surname><given-names>C</given-names></string-name>, <string-name><surname>Pegington</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women</article-title>. <source>Br J Nutr</source><year>2013</year>;<volume>110</volume>:<fpage>1534</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1017/S0007114513000792</pub-id><pub-id pub-id-type="pmid">23591120</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shai</surname><given-names>I</given-names></string-name>, <string-name><surname>Schwarzfuchs</surname><given-names>D</given-names></string-name>, <string-name><surname>Henkin</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet</article-title>. <source>N Engl J Med</source><year>2008</year>;<volume>359</volume>:<fpage>229</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0708681</pub-id><pub-id pub-id-type="pmid">18635428</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hession</surname><given-names>M</given-names></string-name>, <string-name><surname>Rolland</surname><given-names>C</given-names></string-name>, <string-name><surname>Kulkarni</surname><given-names>U</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Systematic review of randomized controlled trials of Low‐Carbohydrate vs. Low‐Fat/Low‐Calorie diets in the management of obesity and its Comorbidities</article-title>. <source>Obes Rev</source><year>2009</year>;<volume>10</volume>:<fpage>36</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1111/j.1467-789X.2008.00518.x</pub-id><pub-id pub-id-type="pmid">18700873</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghaemi</surname><given-names>F</given-names></string-name>, <string-name><surname>Firouzabadi</surname><given-names>FD</given-names></string-name>, <string-name><surname>Moosaie</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effects of a Mediterranean diet on the development of diabetic complications: a longitudinal study from the nationwide diabetes report of the national program for prevention and control of diabetes (NPPCD 2016-2020)</article-title>. <source>Maturitas</source><year>2021</year>;<volume>153</volume>:<fpage>61</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.maturitas.2021.08.003</pub-id><pub-id pub-id-type="pmid">34654529</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="webpage"><article-title>Dose adjustment for normal eating (DAFNE)</article-title>. <comment>n.d.</comment><comment>Available</comment>: <uri xlink:href="https://www.dafneonline.co.uk/">https://www.dafneonline.co.uk/</uri></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ames</surname><given-names>GE</given-names></string-name>, <string-name><surname>Heckman</surname><given-names>MG</given-names></string-name>, <string-name><surname>Grothe</surname><given-names>KB</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Eating self-efficacy: development of a short-form WEL</article-title>. <source>Eat Behav</source><year>2012</year>;<volume>13</volume>:<fpage>375</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.eatbeh.2012.03.013</pub-id><pub-id pub-id-type="pmid">23121791</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Spitzer</surname><given-names>RL</given-names></string-name>, <string-name><surname>Kroenke</surname><given-names>K</given-names></string-name>, <string-name><surname>Williams</surname><given-names>JBW</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A brief measure for assessing generalized anxiety disorder: the GAD-7</article-title>. <source>Arch Intern Med</source><year>2006</year>;<volume>166</volume>:<fpage>1092</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1001/archinte.166.10.1092</pub-id><pub-id pub-id-type="pmid">16717171</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kroenke</surname><given-names>K</given-names></string-name>, <string-name><surname>Spitzer</surname><given-names>RL</given-names></string-name>, <string-name><surname>Williams</surname><given-names>JB</given-names></string-name></person-group>. <article-title>The PHQ‐9: validity of a brief depression severity measure</article-title>. <source>J Gen Intern Med</source><year>2001</year>;<volume>16</volume>:<fpage>606</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1046/j.1525-1497.2001.016009606.x</pub-id><pub-id pub-id-type="pmid">11556941</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <mixed-citation publication-type="webpage"><article-title>National Institute for health and care excellence (NICE)</article-title>. <comment>n.d.</comment><comment>Available</comment>: <uri xlink:href="https://www.nice.org.uk/guidance">https://www.nice.org.uk/guidance</uri></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cradock</surname><given-names>KA</given-names></string-name>, <string-name><surname>ÓLaighin</surname><given-names>G</given-names></string-name>, <string-name><surname>Finucane</surname><given-names>FM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Diet behaviour change techniques in type 2 diabetes: a systematic review and meta-analysis</article-title>. <source>Diabetes Care</source><year>2017</year>;<volume>40</volume>:<fpage>1800</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.2337/dc17-0462</pub-id><pub-id pub-id-type="pmid">29162585</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Michie</surname><given-names>S</given-names></string-name>, <string-name><surname>Abraham</surname><given-names>C</given-names></string-name>, <string-name><surname>Whittington</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effective techniques in healthy eating and physical activity interventions: a meta-regression</article-title>. <source>Health Psychol</source><year>2009</year>;<volume>28</volume>:<fpage>690</fpage>–<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1037/a0016136</pub-id><pub-id pub-id-type="pmid">19916637</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bradley</surname><given-names>C</given-names></string-name>, <string-name><surname>Todd</surname><given-names>C</given-names></string-name>, <string-name><surname>Gorton</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the Addqol</article-title>. <source>Qual Life Res</source><year>1999</year>;<volume>8</volume>:<fpage>79</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1023/a:1026485130100</pub-id><pub-id pub-id-type="pmid">10457741</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lowther</surname><given-names>M</given-names></string-name>, <string-name><surname>Mutrie</surname><given-names>N</given-names></string-name>, <string-name><surname>Loughlan</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Development of a Scottish physical activity questionnaire: a tool for use in physical activity interventions</article-title>. <source>Br J Sports Med</source><year>1999</year>;<volume>33</volume>:<fpage>244</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1136/bjsm.33.4.244</pub-id><pub-id pub-id-type="pmid">10450478</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Medical Research Council</collab></person-group>. <article-title>DAPA measurement Toolkit</article-title>. <comment>n.d.</comment><comment>Available</comment>: <uri xlink:href="https://www.measurement-toolkit.org/anthropometry/subjective-methods/introduction">https://www.measurement-toolkit.org/anthropometry/subjective-methods/introduction</uri></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gormally</surname><given-names>J</given-names></string-name>, <string-name><surname>Black</surname><given-names>S</given-names></string-name>, <string-name><surname>Daston</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The assessment of binge eating severity among obese persons</article-title>. <source>Addict Behav</source><year>1982</year>;<volume>7</volume>:<fpage>47</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/0306-4603(82)90024-7</pub-id><pub-id pub-id-type="pmid">7080884</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saunders</surname><given-names>JB</given-names></string-name>, <string-name><surname>Aasland</surname><given-names>OG</given-names></string-name>, <string-name><surname>Babor</surname><given-names>TF</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption</article-title>. <source>Addiction</source><year>1993</year>;<volume>88</volume>:<fpage>791</fpage>–<lpage>804</lpage>. <pub-id pub-id-type="doi">10.1111/j.1360-0443.1993.tb02093.x</pub-id><pub-id pub-id-type="pmid">8329970</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <label>40</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>U.S. Department of Health and Human Services</collab></person-group>. <article-title>Common terminology criteria for adverse events (CTCAE) version 5.0</article-title>. <comment>n.d.</comment><comment>Available</comment>: <uri xlink:href="https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf</uri></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
